Shenglin Ma

2.3k total citations
92 papers, 1.7k citations indexed

About

Shenglin Ma is a scholar working on Molecular Biology, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Shenglin Ma has authored 92 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 42 papers in Molecular Biology, 36 papers in Pulmonary and Respiratory Medicine and 35 papers in Oncology. Recurrent topics in Shenglin Ma's work include Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (16 papers) and MicroRNA in disease regulation (12 papers). Shenglin Ma is often cited by papers focused on Lung Cancer Treatments and Mutations (25 papers), Lung Cancer Research Studies (16 papers) and MicroRNA in disease regulation (12 papers). Shenglin Ma collaborates with scholars based in China, United States and Thailand. Shenglin Ma's co-authors include Shirong Zhang, Lucheng Zhu, Dan Su, Kan Wu, Bing Xia, Hongfang Zhang, Jianguo Feng, Hao Jiang, Hong Jiang and Yanyan Zhao and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Shenglin Ma

87 papers receiving 1.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Shenglin Ma China 25 818 518 498 459 170 92 1.7k
Chenyue Zhang China 22 680 0.8× 465 0.9× 578 1.2× 303 0.7× 100 0.6× 74 1.4k
Alesha Thai Australia 5 734 0.9× 413 0.8× 610 1.2× 762 1.7× 102 0.6× 9 1.6k
Ximing Xu China 24 896 1.1× 599 1.2× 527 1.1× 324 0.7× 92 0.5× 101 1.6k
Federica Papaccio Italy 21 1.0k 1.2× 594 1.1× 909 1.8× 293 0.6× 161 0.9× 42 2.0k
Maria Pernemalm Sweden 23 1.3k 1.6× 553 1.1× 314 0.6× 295 0.6× 179 1.1× 46 2.0k
Boon-Cher Goh Singapore 25 1.3k 1.6× 771 1.5× 978 2.0× 503 1.1× 158 0.9× 57 2.6k
Shaoyu Yan United States 25 910 1.1× 326 0.6× 595 1.2× 421 0.9× 122 0.7× 39 1.9k
Sara Bravaccini Italy 27 806 1.0× 659 1.3× 922 1.9× 700 1.5× 86 0.5× 125 2.1k
Eloísa Jantus‐Lewintre Spain 29 1.0k 1.3× 923 1.8× 679 1.4× 619 1.3× 148 0.9× 97 2.2k

Countries citing papers authored by Shenglin Ma

Since Specialization
Citations

This map shows the geographic impact of Shenglin Ma's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shenglin Ma with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shenglin Ma more than expected).

Fields of papers citing papers by Shenglin Ma

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shenglin Ma. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shenglin Ma. The network helps show where Shenglin Ma may publish in the future.

Co-authorship network of co-authors of Shenglin Ma

This figure shows the co-authorship network connecting the top 25 collaborators of Shenglin Ma. A scholar is included among the top collaborators of Shenglin Ma based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shenglin Ma. Shenglin Ma is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
3.
Zhu, Lucheng, Kan Wu, Minna Zhang, et al.. (2024). Comprehensive analysis to identify IL7R as a immunotherapy biomarker from pan-cancer analysis to in vitro validation. Discover Oncology. 15(1). 509–509. 2 indexed citations
4.
Zhu, Lucheng, Shenglin Ma, & Bing Xia. (2022). Remarkable response to alectinib for metastatic papillary thyroid cancer with STRN-ALK fusion: A case report. Frontiers in Oncology. 12. 1009076–1009076. 7 indexed citations
5.
6.
Huang, Bo, Yufeng Qian, Shujun Xie, et al.. (2020). Ticagrelor inhibits the NLRP3 inflammasome to protect against inflammatory disease independent of the P2Y12 signaling pathway. Cellular and Molecular Immunology. 18(5). 1278–1289. 49 indexed citations
7.
8.
Zhu, Lucheng, Zhibing Wu, & Shenglin Ma. (2019). Chemotherapeutic hyperthermic intraperitoneal perfusion following radical D2 resection in the treatment of advanced gastric cancer. Annals of Oncology. 30. iv5–iv6. 1 indexed citations
9.
Wu, Kan, Xiao Xu, Lucheng Zhu, et al.. (2018). Radiation pneumonitis in lung cancer treated with volumetric modulated arc therapy. Journal of Thoracic Disease. 10(12). 6531–6539. 13 indexed citations
10.
Wang, Wenzhe, Mengdie Fang, Wei Wang, et al.. (2018). Clinical significance of reduced GPRC5A expression in surgically resected non‑small cell lung cancer. Oncology Letters. 17(1). 502–507. 7 indexed citations
11.
Zhao, Yanyan, Shirong Zhang, Zhibing Wu, et al.. (2017). P2.05-029 Microwave Thermal Therapy Enhances Radiosensitivity of Highly Invasive Human Non-Small Cell Lung Cancer H460 Cells via Inhibiting DNA Repair. Journal of Thoracic Oncology. 12(1). S1048–S1048. 2 indexed citations
12.
Xia, Bing, Shirong Zhang, & Shenglin Ma. (2017). Management of non-small cell lung cancer with EGFR mutation: the role of radiotherapy in the era of tyrosine kinase inhibitor therapy—opportunities and challenges. Journal of Thoracic Disease. 9(9). 3385–3393. 9 indexed citations
13.
Xu, Yasi, Shirong Zhang, Bing Xia, Lucheng Zhu, & Shenglin Ma. (2017). P2.05-005 Mechanism of Radiotherapy in Reduction/Delay of T790M-Mediated EGFR TKI Resistance. Journal of Thoracic Oncology. 12(1). S1033–S1033. 1 indexed citations
14.
Jian, Hong, Wěi Li, Zhiyong Ma, et al.. (2017). Intercalating and maintenance gefitinib plus chemotherapy versus chemotherapy alone in selected advanced non-small cell lung cancer with unknown EGFR status. Scientific Reports. 7(1). 8483–8483. 6 indexed citations
15.
Li, Weili, Wenzhe Wang, Mingjian Ding, et al.. (2016). MiR-1244 sensitizes the resistance of non-small cell lung cancer A549 cell to cisplatin. Cancer Cell International. 16(1). 30–30. 43 indexed citations
16.
Zhang, Fanrong, Weihui Zheng, Lisha Ying, et al.. (2016). A Nomogram to Predict Brain Metastases of Resected Non-Small Cell Lung Cancer Patients. Annals of Surgical Oncology. 23(9). 3033–3039. 56 indexed citations
17.
Yang, Shao‐Yu, et al.. (2016). Proteins associated with EGFR-TKIs resistance in patients with non-small cell lung cancer revealed by mass spectrometry. Molecular Medicine Reports. 14(5). 4823–4829. 4 indexed citations
18.
Ma, Shenglin, et al.. (2015). Effect of interleukin-2 treatment combined with magnetic fluid hyperthermia on Lewis lung cancer-bearing mice. Biomedical Reports. 4(1). 59–62. 13 indexed citations
19.
Deng, Qinghua, et al.. (2014). Postoperative radiotherapy following mastectomy for patients with left-sided breast cancer: A comparative dosimetric study. Medical dosimetry. 40(3). 190–194. 23 indexed citations
20.
Ying, Lisha, Dan Su, Jianqing Zhu, et al.. (2013). Genotyping of stathmin and its association with clinical factors and survival in patients with ovarian cancer. Oncology Letters. 5(4). 1315–1320. 6 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Chenyue Zhang Breakdown of academic impact, for papers by Alesha Thai Breakdown of academic impact, for papers by Ximing Xu Breakdown of academic impact, for papers by Federica Papaccio Breakdown of academic impact, for papers by Maria Pernemalm Breakdown of academic impact, for papers by Boon-Cher Goh Breakdown of academic impact, for papers by Shaoyu Yan Breakdown of academic impact, for papers by Sara Bravaccini Breakdown of academic impact, for papers by Eloísa Jantus‐Lewintre
Rankless by CCL
2026